Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Rhea-AI Summary
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, after market close. The company will hold a conference call and webcast to discuss the results and provide a business update on Friday, May 16, 2025, at 10:00 AM ET. Interested parties can access the conference call via U.S. toll-free number 1-877-877-1275 or international number 1-412-858-5202.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BFRI gained 1.86%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025. The results will be released after the market close on Thursday, May 15 and the company will host a conference call on Friday, May 16 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event: | Biofrontera Inc. First Quarter 2025 Financial Results and Business Update Conference Call |
Date: | Friday, May 16, 2025 |
Time: | 10:00am ET |
Conference Call: | 1-877-877-1275 (U.S.) |
Webcast: | Webcast | First Quarter 2025 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on ACCESS Newswire
FAQ
When will Biofrontera (BFRI) release Q1 2025 earnings?
What time is Biofrontera's (BFRI) Q1 2025 earnings call?
How can I join Biofrontera's (BFRI) Q1 2025 earnings call?
What does Biofrontera (BFRI) specialize in?
